By Nick Stride
Friday 7th March 2003 |
Text too small? |
Wrightson announced its $1.31-a-share stand in the market on Wednesday and finished the day with 15.05%.
It said its Genesis investment was aimed at "providing an impetus" for more collaboration in agricultural biotechnology.
The move is likely to have been approved by its 19.9% shareholder, Fonterra. Both Wrightson and Fonterra subsidiary RD1 have biotech research arms and market observers have speculated Fonterra will eventually take over Wrightson and separate the rural services and biotech divisions.
Genesis' shares have languished below the $1.70 value of its cash reserves of about $36.3 million. They traded at 97c immediately before the Wrightson stand was announced.
British trials of Genesis' Avac eczema treatment showed the drug to be safe and well-tolerated.
No comments yet
Fonterra appoints permanent COO
Manawa Energy FY24 Annual Results & Webcast Details
Seeka Provides the Results of Meeting - ASM
April 19th Morning Report
PGW Guidance Update
CNU - Commerce Commission releases draft expenditure decision
Spark announces departure of Product Director
TGG - T&G appoints new Director
April 18th Morning Report
SKC - APPOINTMENT OF CHIEF EXECUTIVE OFFICER